Related references
Note: Only part of the references are listed.Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
Renli Teng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Heart rate deceleration after exercise predicts patients most likely to respond to cardiac resynchronisation therapy
D. E. Thomas et al.
HEART (2010)
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
P. Michael Ho et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Antiplatelet therapy in acute coronary syndromes
Colin M. Barker et al.
Current Cardiology Reports (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Antiplatelet treatment for coronary heart disease
N. Clappers et al.
HEART (2007)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
DL Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
ZM Chen et al.
LANCET (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
HC Diener et al.
LANCET (2004)
Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions
D Fischetti et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2000)
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
C Müller et al.
CIRCULATION (2000)